Clene Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $119,000, 60% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
|---|---|---|---|---|---|---|---|
| Revenue |
0
|
0
|
0
|
1
|
0
|
1
|
0
|
| Product |
0
+33.3%
share 72.3%
|
0
-49.8%
share 59.5%
|
0
-52.4%
share 69.3%
|
0
+51.4%
share 76.1%
|
0
-42.3%
share 69.6%
|
1
+223.9%
share 78.8%
|
0
share 85.4%
|
| Royalty |
0
-22.4%
share 27.7%
|
0
-22.9%
share 40.5%
|
0
-32.7%
share 30.7%
|
0
+8.3%
share 23.9%
|
0
-5.9%
share 30.4%
|
0
+410.0%
share 21.2%
|
0
share 14.6%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLNN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1822791
- Former names
- Chelsea Worldwide Inc. (until Dec 18, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.